ELISA kit for quantitative measurement of human NGAL in clinical research and Phase 1 human clinical trials. Supports biomarker validation and research applications in kidney injury assessment.
Manufactured by
BioPorto Diagnostics
United States
ProNephro AKI (NGAL) is designed to aid in the risk assessment of acute kidney injury (AKI) in ICU patients 3 months to 22 years. A low NGAL value indicates a low risk of AKI, allowing for confident use of interventions such as fluids, diuretics, or nephrotoxic medications. Elevated NGAL values signal a high risk of developing AKI and can trigger nephrology consults and interventions 2-3 days before serum creatinine rises.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
1 of 1 closest product alternatives
© 2026 Suplivia · Home · Browse Products